Crossroads in GDNF therapy for Parkinson's disease

Movement Disorders

Volumn 21, Issue 2, 2006, Pages 136-141

  Sherer, Todd B ^a   Fiske, Brian K ^a   Svendsen, Clive N ^b   Lang, Anthony E ^c   Langston, J William ^d  

^a THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d PARKINSON S INSTITUTE   (United States)

Author keywords

Clinical trials; Drug delivery; GDNF; Neuroimaging

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUTRALIZING ANTIBODY; PLACEBO;

BLOOD BRAIN BARRIER; CEREBELLUM DISEASE; CLINICAL TRIAL; DOPAMINE RELEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; NEUROIMAGING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CATHETERS, INDWELLING; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTORS; HUMANS; MAGNETIC RESONANCE IMAGING; MULTICENTER STUDIES; NERVE REGENERATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PUTAMEN;

EID: 33644938239     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20861     Document Type: Review

References (26)

1. Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132.
2. Grondin R, Zhang Z, Yi A, et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002;125(Pt. 10):2191-2201.
3. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73.
4. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46: 419-423.
5. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nat Med 2003;9:589-595.
6. Slevin JT, Gerhardt GA, Smith CD, et al. Unilateral intraputamenal GDNF improves bilateral motor functions in patients with Parkinson's disease. J Neurosurg 2005;102:216-222.
7. Lang AE, Gill S, Patel N, et al. Randomized controlled trial of intraputamenal GDNF infusion in Parkinson's disease. Ann Neurol (in press).
8. Tatarewicz SM, Wei X, Moxness M, et al. Neutralizing antibody development and class switching in clinical patients with idiopathic Parkinson's receiving r-metHuGDNF via intraputamenal infusion. Soc Neurosci Abst 2005;899:6.
9. Patel NK, Bunnage M, Plaha P, et al. Intraputamenal infusion of glial cell-line derived neurotrophic factor in Parkinson's disease: a two-year clinical, cognitive, and quality of life outcome study. Ann Neuol 2005;57:298-302.
10. Hamilton JF, Morrison PF, Chen MY, et al. Heparin coinfusion during convection-enhanced delivery increases the distribution of glial-derived neurotrophic factor ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp Neurol 2001;168:155-161.
11. Degen JW, Walbridge S, Vortmeyer AO, et al. Safety and efficacy of convection-enhanced delivery of gemcitab carboplatin in a malignant glioma model in rats. J Neurosurg 2003;99:893-898.
12. Eckert T, Eidelberg D. The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson's disease and multiple system atrophy. Clin Auton Res 2004;14:84-91.
13. Goetz CG, Janko K, Blasucci L, et al. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord 2003; 18:1146-1149.
14. Hauser RA, Watts RL, Freeman TB, et al. A double-blind, randomized, controlled, multicenter clinical study of the safety and efficacy of transplanted fetal porcine ventral mesencephalic cells versus imitation surgery in patients with Parkinson's disease. Mov Disord 2001;16:983-984.
15. De la Fuente-Fernandez R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry 2004;15:67-71.
16. Benedetti F, Colloca L, Torre E, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci 2004;7:587-588.
17. McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double blind placebo surgery trial. Arch Gen Psychiatry 2004;61:412-420.
18. Love S, Plaha P, Patel NK, et al. Neuronal sprouting induced by glial-derived neurotrophic factor in human brain. Nat Med 2005; 11:703-704.
19. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
20. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
21. Schellekens H. Relationship between biopharmaceutical immunogenicity of epoiten-alpha and pure cell aplasia. Curr Med Res Opin 2003;19:433-434.
22. Florez-McClure ML, Lingeman DA, Chu CT, et al. The p75 neurotrophin receptor can induce autophagy and death of cerebellar Purkinje neurons. J Neurosci 2004;24:4498-4509.
23. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290:767-773.
24. Behrstock S, Ebert A, Vosberg S, et al. Human neural progenitors deliver glial cell-line derived neurotrophic factor (GDNF) to Parkinsonian rodents and aged primates. Gene Ther 2005; doi: 10.1038/sj.gt.3302679.
25. Kishima H, Poyot T, Bloch J, et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis 2004;16:428-439.
26. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal system is not enough. Lancet Neurol 2004;3: 309-316.